-
Product Insights
Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Pulmonary Fibrosis Clinical Trial Report Overview A total of 713 idiopathic pulmonary fibrosis clinical trials were conducted as of January 2024. The Idiopathic Pulmonary Fibrosis clinical trial report provides a comprehensive understanding of the idiopathic pulmonary fibrosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICON-1 in Choroidal Neovascularization
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICON-1 in Choroidal Neovascularization report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewChoroidal Neovascularization – Drugs In Development, 2024
Empower your strategies with our Choroidal Neovascularization – Drugs In Development, 2024 report and make more profitable business decisions. Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid, the pigmented vascular layer of tissue behind the retina. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-vascular endothelial growth factor (anti-VEGF) agents, laser photocoagulation, and photodynamic therapy. The Choroidal Neovascularization drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewNorovirus Infections – Drugs In Development, 2024
Empower your strategies with our Norovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Noroviruses are nonenveloped, positive-sense, single-stranded RNA viruses belonging to the Caliciviridae viral family. It is a highly contagious virus causing gastroenteritis, leading to stomach and intestinal inflammation. A common cause of outbreaks of diarrhea and vomiting in schools, cruise ships, hospitals, and community gatherings, it's nicknamed the "winter vomiting bug" due to prevalence in colder months. Symptoms encompass nausea, vomiting, diarrhea, and...
-
Product Insights
Sharp Makueni Solar PV Park
Sharp Makueni Solar PV Park is a solar PV project located in Makueni, Kenya. The project is owned by Legacy Energy Group LLC; Rareh Icon Solar Ltd; responsAbility Africa Ltd.; Sharp Energy Solutions Corp and is developed by Legacy Energy Group LLC; Rareh Icon Solar Ltd; Sharp Energy Solutions Corp. The project is at the permitting stage. Empower your strategies with our Sharp Makueni Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report...
-
Product Insights
Ablation Equipment Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Ablation Equipment Pipeline Market Report Overview An Ablation Equipment is a device used to surgically remove a body tissue. The Ablation Equipment pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The US ·       Europe...
-
Product Insights
SELCHP Plant
SELCHP Plant is a biopower project located in United Kingdom. The project is owned by iCON Infrastructure LLP; Onyx Selchp and was developed by Martin Engineering Co Ltd. The project came online in 1994. Empower your strategies with our SELCHP Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Respiratory Syncytial Virus Clinical Trials Overview The report provides an overview of the Respiratory Syncytial Virus (RSV) clinical trial scenario and top-line data relating to the clinical trials on it. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions ·       Asia-Pacific ·       Europe ·       North...
-
Product Insights
Interstitial Cystitis (Painful Bladder Syndrome) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Interstitial Cystitis Clinical Trials Overview The report provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) clinical trial scenario and top-line data relating to the clinical trials. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions ·       North America ·       Asia-Pacific ·       Europe ·       ...